
New Jersey biotech nets $50M+ BARDA contract for respiratory candidate
Eagle Pharmaceuticals is keeping an eye on Enalare Therapeutics’ lead respiratory candidate, and apparently, so is the US government. The New Jersey-based biotech struck a deal with BARDA worth up to $50.3 million to develop […]